Abstract
e14064 Background: Medullomyoblastoma is a rare cerebellar cancer theorized to be of teratomatous origin and a more aggressive variant of medulloblastoma primarily affecting children under 10 Despite treatment with excision surgery, the survival period is less than 1 year. There is no standard treatment and previous studies have only looked at median follow-up and radiotherapy. A study using National Cancer Database data would be beneficial to examine the impact of demographic factors on risk and treatment. Methods: A retrospective cohort study using data from the National Cancer Database from 2005 to 2019 analyzed 19 patients diagnosed with medullomyoblastoma. The study examined demographic factors such as age, sex, race, Hispanic origin, insurance coverage, distance from facility, and Charlson-Deyo score through descriptive statistics and evaluated trends in incidence through regression analysis. Results: A total of 19 patients were identified in the database with a confirmed diagnosis of medullomyoblastoma between 2005 – 2019, with a slightly declining incidence of patients diagnosed per year (R2 = 0.155). The average age of diagnosis was 13.5 years (SD = 12.5, range = 1 – 44 years), with 52.6% of affected individuals being children under the age of 10. Males and females were affected relatively equally (52.6% and 47.4%, respectively). The top primary site was the cerebellum (84.2%). Most individuals (94.7%) had Charlson-Deyo comorbidity scores of 0. The majority of individuals (68.4%) received treatment as some form of tumor excision surgery (local tumor excision with or without combination of photodynamic therapy, electrocautery, cryosurgery, wide excision, or radical excision). The majority of the patients were non-Hispanic and White (94.7%). A higher percentage of patients were privately insured (68.4%) than those who were uninsured or insured by Medicaid. The majority (84.2%) of patients lived in a metropolitan area. Patients lived an average of 48.6 miles (SD = 57.1, range = 0.6 – 189.5) from the treatment facility. No patients received palliative care. Conclusions: To the best of our knowledge, this is the first NCDB study on medullomyoblastoma, filling a crucial gap in knowledge. Results show the majority of patients are non-Hispanic White children, with primary site at the cerebellum, similar to previous case reports. For the first time, socioeconomic characteristics of medullomyoblastoma patients have been documented, such as the majority of patients being privately insured living in metropolitan areas. Treatment-wise, patients receive tumor excision surgery in the form of localized excisions or combination therapies. Currently, more attention is paid to pediatric cases, so a study on adult incidences would provide a more holistic assessment of the cancer. Further investigation is needed to understand the effect of demographic/socioeconomic factors on rarity, earlier diagnosis, and treatment.